article thumbnail

CDMO Selection: The Ultimate Checklist

Drug Patent Watch

This growth has created a competitive landscape where pharmaceutical companies must carefully evaluate and select the right CDMO partner to ensure the success of their projects. Pharmaceutical companies should look for CDMOs with a proven track record of working with various molecules and pharmaceutical companies.

article thumbnail

The Benefits of Integrated CDMO Services: Streamlining Drug Development and Manufacturing

Drug Patent Watch

The Rise of Integrated CDMOs The global biotechnology and pharmaceutical services outsourcing market size was valued at $70.48 As a result, many companies are turning to integrated CDMOs to simplify their outsourcing processes and improve efficiency. billion in 2022 and is expected to grow at a compound annual growth rate of 5.3%

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

How AI will reshape pharma by 2025

Drug Target Review

These digital twins allow pharmaceutical companies to design clinical trials with fewer participants, while still providing reliable evidence to assess a drugs effectiveness. Regulators care a lot about controlling the Type 1 error rate of the clinical trial, Smith notes.

article thumbnail

Understanding the Regulatory Environment in Japan for Generic Drug Development

Drug Patent Watch

This article aims to provide a comprehensive overview of the key aspects of the regulatory framework, highlighting the requirements and challenges faced by pharmaceutical companies seeking to introduce generic drugs into the Japanese market. Retrieved from [link] Japan Pharmaceutical Manufacturers Association. Freyr Solutions.

article thumbnail

Protecting Your Drug Patent in Global Markets: Strategies and Challenges

Drug Patent Watch

This is a nightmare scenario for any pharmaceutical company, and it's a reality that many face every day. One key strategy is to conduct thorough market research and stay up-to-date on the latest patent laws and regulations in each country where you plan to operate.

article thumbnail

The Issue with Reissue: PTE Edition

FDA Law Blog: Biosimilars

Koblitz Integral to the careful balance Congress struck when passing the Hatch-Waxman Amendments, the patent term extension (PTE) is intended to restore patent life that was consumed during regulatory review of an FDA-regulated product. The Court thus explained that interpreting the patent in 35 U.S.C.

article thumbnail

Navigating the Challenges and Opportunities of the PICO Framework in the New EU HTA Regulation

PPD

The European Union (EU) is on the verge of a significant shift as it prepares to implement new health technology assessment (HTA) regulations in 2025. Challenges and opportunities of the new EU HTA regulation The implementation of centralized HTA presents both opportunities and challenges for pharmaceutical companies.